Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients

Jong Hoon Park, Kisoo Pahk, Sungeun Kim, Sang Moo Lim, Gi Jeong Cheon, Yeon Hee Park, Seung Sook Lee, Jae-Gol Choe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of the present study was to evaluate the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings in patients with T-lymphoblastic lymphoma (T-LBL). In total, 9 patients with histopathologically confirmed T-LBL were included in the study. Bone marrow (BM) involvement and leukemic transformation (LT) were evaluated through iliac crest marrow biopsy and peripheral blood blast count. FDG-PET scans were performed at the initial pre-treatment point. Two experienced nuclear medicine physicians evaluated the FDG-PET images by visual analysis and using the maximum standardized uptake values (SUVmax) of the malignant lesions. Overall, 8 out 9 patients presented with BM involvement; 7 showed LT, while 1 showed BM involvement without LT. All involved T-LBL lesions were FDG-avid with variable uptake. The mean SUVmax was 6.4-3.3. T-LBL patients with BM involvement showed diffuse or nodular marrow uptake. In addition, all the patients with LT showed diffuse marrow FDG activity. However, the patient with BM involvement but no LT showed nodular FDG uptake in the marrow. In conclusion, the present study indicates that it is possible to use FDG-PET for the evaluation of the disease extent of T-LBL. Furthermore, the imaging technique could provide a diagnostic clue for determining BM involvement or LT.

Original languageEnglish
Pages (from-to)1620-1622
Number of pages3
JournalOncology Letters
Volume12
Issue number2
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Fluorodeoxyglucose F18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Positron-Emission Tomography
Bone Marrow
Nuclear Medicine
Physicians
Biopsy

Keywords

  • Fluorodeoxyglucose-positron emission tomography
  • Lymphoma
  • Positron emission tomography
  • T-lymphoblastic lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients. / Park, Jong Hoon; Pahk, Kisoo; Kim, Sungeun; Lim, Sang Moo; Cheon, Gi Jeong; Park, Yeon Hee; Lee, Seung Sook; Choe, Jae-Gol.

In: Oncology Letters, Vol. 12, No. 2, 01.08.2016, p. 1620-1622.

Research output: Contribution to journalArticle

Park, Jong Hoon ; Pahk, Kisoo ; Kim, Sungeun ; Lim, Sang Moo ; Cheon, Gi Jeong ; Park, Yeon Hee ; Lee, Seung Sook ; Choe, Jae-Gol. / Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients. In: Oncology Letters. 2016 ; Vol. 12, No. 2. pp. 1620-1622.
@article{f58932abe18f4975b564f7b17bac60a9,
title = "Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients",
abstract = "The purpose of the present study was to evaluate the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings in patients with T-lymphoblastic lymphoma (T-LBL). In total, 9 patients with histopathologically confirmed T-LBL were included in the study. Bone marrow (BM) involvement and leukemic transformation (LT) were evaluated through iliac crest marrow biopsy and peripheral blood blast count. FDG-PET scans were performed at the initial pre-treatment point. Two experienced nuclear medicine physicians evaluated the FDG-PET images by visual analysis and using the maximum standardized uptake values (SUVmax) of the malignant lesions. Overall, 8 out 9 patients presented with BM involvement; 7 showed LT, while 1 showed BM involvement without LT. All involved T-LBL lesions were FDG-avid with variable uptake. The mean SUVmax was 6.4-3.3. T-LBL patients with BM involvement showed diffuse or nodular marrow uptake. In addition, all the patients with LT showed diffuse marrow FDG activity. However, the patient with BM involvement but no LT showed nodular FDG uptake in the marrow. In conclusion, the present study indicates that it is possible to use FDG-PET for the evaluation of the disease extent of T-LBL. Furthermore, the imaging technique could provide a diagnostic clue for determining BM involvement or LT.",
keywords = "Fluorodeoxyglucose-positron emission tomography, Lymphoma, Positron emission tomography, T-lymphoblastic lymphoma",
author = "Park, {Jong Hoon} and Kisoo Pahk and Sungeun Kim and Lim, {Sang Moo} and Cheon, {Gi Jeong} and Park, {Yeon Hee} and Lee, {Seung Sook} and Jae-Gol Choe",
year = "2016",
month = "8",
day = "1",
doi = "10.3892/ol.2016.4806",
language = "English",
volume = "12",
pages = "1620--1622",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of T-lymphoblastic lymphoma patients

AU - Park, Jong Hoon

AU - Pahk, Kisoo

AU - Kim, Sungeun

AU - Lim, Sang Moo

AU - Cheon, Gi Jeong

AU - Park, Yeon Hee

AU - Lee, Seung Sook

AU - Choe, Jae-Gol

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The purpose of the present study was to evaluate the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings in patients with T-lymphoblastic lymphoma (T-LBL). In total, 9 patients with histopathologically confirmed T-LBL were included in the study. Bone marrow (BM) involvement and leukemic transformation (LT) were evaluated through iliac crest marrow biopsy and peripheral blood blast count. FDG-PET scans were performed at the initial pre-treatment point. Two experienced nuclear medicine physicians evaluated the FDG-PET images by visual analysis and using the maximum standardized uptake values (SUVmax) of the malignant lesions. Overall, 8 out 9 patients presented with BM involvement; 7 showed LT, while 1 showed BM involvement without LT. All involved T-LBL lesions were FDG-avid with variable uptake. The mean SUVmax was 6.4-3.3. T-LBL patients with BM involvement showed diffuse or nodular marrow uptake. In addition, all the patients with LT showed diffuse marrow FDG activity. However, the patient with BM involvement but no LT showed nodular FDG uptake in the marrow. In conclusion, the present study indicates that it is possible to use FDG-PET for the evaluation of the disease extent of T-LBL. Furthermore, the imaging technique could provide a diagnostic clue for determining BM involvement or LT.

AB - The purpose of the present study was to evaluate the fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings in patients with T-lymphoblastic lymphoma (T-LBL). In total, 9 patients with histopathologically confirmed T-LBL were included in the study. Bone marrow (BM) involvement and leukemic transformation (LT) were evaluated through iliac crest marrow biopsy and peripheral blood blast count. FDG-PET scans were performed at the initial pre-treatment point. Two experienced nuclear medicine physicians evaluated the FDG-PET images by visual analysis and using the maximum standardized uptake values (SUVmax) of the malignant lesions. Overall, 8 out 9 patients presented with BM involvement; 7 showed LT, while 1 showed BM involvement without LT. All involved T-LBL lesions were FDG-avid with variable uptake. The mean SUVmax was 6.4-3.3. T-LBL patients with BM involvement showed diffuse or nodular marrow uptake. In addition, all the patients with LT showed diffuse marrow FDG activity. However, the patient with BM involvement but no LT showed nodular FDG uptake in the marrow. In conclusion, the present study indicates that it is possible to use FDG-PET for the evaluation of the disease extent of T-LBL. Furthermore, the imaging technique could provide a diagnostic clue for determining BM involvement or LT.

KW - Fluorodeoxyglucose-positron emission tomography

KW - Lymphoma

KW - Positron emission tomography

KW - T-lymphoblastic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84977178274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977178274&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.4806

DO - 10.3892/ol.2016.4806

M3 - Article

VL - 12

SP - 1620

EP - 1622

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -